scholarly journals KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

2011 ◽  
Vol 104 (6) ◽  
pp. 1020-1026 ◽  
Author(s):  
N Knijn ◽  
L J M Mekenkamp ◽  
M Klomp ◽  
M E Vink-Börger ◽  
J Tol ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Mutation Analysis ◽  
Kras Mutation ◽  
Colorectal Cancer Patients

scholarly journals Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience

2016 ◽  
Vol 23 (1) ◽  
pp. 24-34 ◽  
Author(s):  
Edita Baltruškevičienė ◽  
Ugnius Mickys ◽  
Tadas Žvirblis ◽  
Rokas Stulpinas ◽  
Teresė Pipirienė Želvienė ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Mutation Analysis ◽  
Kras Mutation ◽  
Pik3ca Mutation ◽  
Kras Mutations ◽  
Cox Regression Analysis ◽  
Pik3ca Mutations ◽  
Colorectal Cancer Patients

Background. KRAS mutation is an important predictive and prognostic factor for patients receiving anti-EGFR therapy. An expanded KRAS, NRAS, BRAF, PIK3CA mutation analysis provides additional prognostic information, but its role in predicting bevacizumab efficacy is unclear. The aim of our study was to evaluate the incidence of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving first line oxaliplatin based chemotherapy with or without bevacizumab and to evaluate their prognostic and predictive significance. Methods. 55 patients with the  first-time diagnosed CRC receiving FOLFOX ± bevacizumab were involved in the study. Tumour blocks were tested for KRAS mutations in exons 2, 3 and 4, NRAS mutations in exons 2, 3 and 4, BRAF mutation in exon 15 and PIK3CA mutations in exons 9 and 20. The association between mutations and clinico-pathological factors, treatment outcomes and survival was analyzed. Results. KRAS mutations were detected in 67.3% of the  patients, BRAF in 1.8%, PIK3CA in 5.5% and there were no NRAS mutations. A  significant association between the  high CA  19–9 level and KRAS mutation was detected (mean CA 19–9 levels were 276 and 87 kIU/l, respectively, p  =  0.019). There was a  significantly higher response rate in the KRAS, NRAS, BRAF and PIK3CA wild type cohort receiving bevacizumab compared to any gene mutant type (100 and 60%, respectively, p = 0.030). The univariate Cox regression analysis did not confirm KRAS and other tested mutations as prognostic factors for PFS or OS. Conclusions. Our study revealed higher KRAS and lower NRAS, BRAF and PIK3CA mutation rates in the  Lithuanian population than those reported in the  literature. KRAS mutation was associated with the high CA 19–9 level and mucinous histology type, but did not show any predictive or prognostic significance. The  expanded KRAS, NRAS, BRAF and PIK3CA mutation analysis provided additional significant predictive information.

scholarly journals Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Ziyao Li ◽  
Shaofei Li ◽  
Hangbo Tao ◽  
Yixiang Zhan ◽  
Kemin Ni ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Hepatitis B ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Hepatic Metastasis ◽  
High Titer ◽  
Poor Overall Survival ◽  
Free Survival ◽  
Colorectal Cancer Patients

Abstract Background There have been controversial voices on if hepatitis B virus infection decreases the risk of colorectal liver metastases or not. This study aims to the find the association between HBV infection and postoperative survival of colorectal cancer and the risk of liver metastases in colorectal cancer patients. Methods Patients who underwent curative surgical resection for colorectal cancer between January 2011 and December 2012 were included. Patients were grouped according to anti-HBc. Differences in overall survival, time to progress, and hepatic metastasis-free survival between groups and significant predictors were analyzed. Results Three hundred twenty-seven colorectal cancer patients were comprised of 202 anti-HBc negative cases and 125 anti-HBc positive cases, and anti-HBc positive cases were further divided into high-titer anti-HBc group (39) and low-titer anti-HBc group (86). The high-titer anti-HBc group had significantly worse overall survival (5-Yr, 65.45% vs. 80.06%; P < .001), time to progress (5-Yr, 44.26% vs. 84.73%; P < .001), and hepatic metastasis-free survival (5-Yr, 82.44% vs. 94.58%; P = .029) than the low-titer group. Multivariate model showed anti-HBc ≥ 8.8 S/CO was correlated with poor overall survival (HR, 3.510; 95% CI, 1.718–7.17; P < .001), time to progress (HR, 5.747; 95% CI, 2.789–11.842; P < .001), and hepatic metastasis-free survival (HR, 3.754; 95% CI, 1.054–13.369; P = .041) in the anti-HBc positive cases. Conclusions Higher titer anti-HBc predicts a potential higher risk of liver metastases and a worse survival in anti-HBc positive colorectal cancer patients.

scholarly journals Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases

2012 ◽  
Vol 6 (1) ◽  
pp. 6
Author(s):  
Luigi Rossi ◽  
Angelo Zullo ◽  
Federica Zoratto ◽  
Anselmo Papa ◽  
Martina Strudel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Target Therapy ◽  
Resection Rate ◽  
Biological Drugs ◽  
Unresectable Colorectal Liver Metastases ◽  
Neo Adjuvant Chemotherapy ◽  
Colorectal Cancer Patients

Although surgery is the most effective treatment for liver metastases in colorectal cancer patients, only 15-20% of these patients are suitable for a radical surgical approach, and metastases recurrence may occur at follow up. In the last decade, the use of pre-operative chemotherapy in combination with new biological drugs has been introduced. We reviewed data of neo-adjuvant chemotherapy strategies aimed at increasing the resection rate of liver metastases in colorectal cancer patients who were initially considered unresectable.

Liver-First Approach in Treatment of Colorectal Cancer Patients with Synchronous Liver Metastases

2020 ◽  
Vol 46 (2) ◽  
pp. e79
Author(s):  
Zaurbek Dudaev ◽  
Viacheslav Aliev ◽  
Zaman Mamedli ◽  
Danil Podluzhny ◽  
Islam Tataev ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Synchronous Liver Metastases ◽  
Colorectal Cancer Patients

The Role of Big Endothelin-1 in Colorectal Cancer

2002 ◽  
Vol 17 (4) ◽  
pp. 268-274 ◽  
Author(s):  
C. Arun ◽  
B. Swift ◽  
K.E. Porter ◽  
K.P. West ◽  
N.J.M. London ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Plasma Concentration ◽  
Liver Metastases ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Hepatic Metastases ◽  
Plasma Samples ◽  
Median Score ◽  
Endothelin 1 ◽  
Colorectal Cancer Patients

Introduction Changes in liver blood flow caused by an unknown splanchnic vasoconstrictor have been noted in colorectal cancer patients with liver metastases. This prospective study was performed to assess whether plasma levels of big endothelin-1 (big ET-1) were raised in patients with colorectal cancer. Methods Plasma samples from peripheral vein of patients who underwent surgery for primary colorectal cancer (n=60) and those with known colorectal liver metastases (n=45) for a period of 15 months were taken prior to treatment and compared to age- and sex-matched controls (n=20). Plasma samples were analysed by using a single-step sandwich enzyme immunoassay. Immunohistochemistry and in situ hybridisation were also performed on tumour sections to investigate the expression of ET-1 by cancer cells. Results The median (range) plasma concentration of big ET-1 in controls was 2.1 pg/mL (1.2–13.4 pg/mL). The median (range) plasma concentration of big ET-1 in colorectal cancer patients with no overt hepatic metastases was 3.8 pg/mL (1.2–15.8 pg/mL), p=0.002, and the median (range) plasma concentration of big ET-1 in colorectal cancer patients with hepatic metastases was 5.2 pg/mL (1.7–30 pg/mL), p=0.0001; both were significantly elevated compared to the control group. A significant difference in immunostaining for big ET-1 was noted between paired normal colonic mucosa (median score-1) and tumour sections (median score-3), p=0.01. Conclusion This study has demonstrated elevated concentrations of big ET-1 in colorectal cancer patients, especially in those with hepatic metastases. Upregulation of ET activity in colorectal cancer could be inferred by the increased immunostaining of big ET-1 in cancer cells. Therefore, plasma big ET-1 levels should be evaluated as a potential tumour marker for the identification of hepatic metastases at an earlier stage.

Primary tumor location impacts survival in colorectal cancer patients after resection of liver metastases

2020 ◽  
Vol 122 (4) ◽  
pp. 745-752
Author(s):  
Katherine Bingmer ◽  
Asya Ofshteyn ◽  
Jonathan T. Bliggenstorfer ◽  
William Kethman ◽  
John B. Ammori ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Tumor Location ◽  
Primary Tumor Location ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document